SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scott_jiminez who started this subject9/27/2000 8:42:53 AM
From: scott_jiminez   of 278
 
Yesyerday's announcement by Biogen of the promising Avonex findings in large part reinforces recent reports in the literature (for example ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10854652&dopt=Abstract) and underscores the rationale for expediting broader indications. IFN-ß1a is one of the very few clinically successful anti-demyelinating approaches thus far and it's application remains largely restricted to relapsing patients. The benefits to this population have been enormous. The latest indication for those at high risk for MS following a monosymptomatic event suggest an aggressive, almost proactive, treatment regime will also produce significant amelioration. This is a giant leap forward in the approach towards progressive neuropathologies.

One could only hope that other neurological diseases, specifically the neurodegenerative class, can also be attenuated by interfering with cytokines and other potentially toxic mediators released during chronic inflammation.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News